Overexpression of the IGF-II/M6P receptor in mouse fibroblast cell lines differentially alters expression profiles of genes involved in Alzheimer's disease-related pathology.
Alzheimer's disease (AD) is the most common type of senile dementia affecting elderly people. The processing of amyloid precursor protein (APP) leading to the generation of β-amyloid (Aβ) peptide contributes to neurodegeneration and development of AD pathology. The endocytic trafficking pathway, which comprises of the endosomes and lysosomes, acts as an important site for Aβ generation, and endocytic dysfunction has been linked to increased Aβ production and loss of neurons in AD brains. Since insulin-like growth factor-II (IGF-II) receptor plays a critical role in the transport of lysosomal enzymes from the trans-Golgi network to endosomes, it is likely that the receptor may have a role in regulating Aβ metabolism in AD pathology. However, very little is known on how altered levels of the IGF-II receptor can influence the expression/function of various molecules involved in AD pathology. To address this issue, we evaluated the expression profiles of 87 selected genes related to AD pathology in mouse fibroblast MS cells that are deficient in murine IGF-II receptor and corresponding MS9II cells overexpressing ∼ 500 times the human IGF-II receptors. Our results reveal that an elevation in IGF-II receptor levels alters the expression profiles of a number of genes including APP as well as enzymes regulating Aβ production, degradation and clearance mechanisms. Additionally, it influences the expression of various lysosomal enzymes and protein kinases that are involved in Aβ toxicity. IGF-II receptor overexpression also alters expression of several genes involved in intracellular signalling as well as cholesterol metabolism, which play a critical role in AD pathology. The altered gene profiles observed in this study closely match with the corresponding protein levels, with a few exceptions. These results, taken together, suggest that an elevation in IGF-II receptor levels can influence the expression profiles of transcripts as well as proteins that are involved in AD pathogenesis.
Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada; Centre for Prions and Protein Folding Diseases, University of Alberta, Edmonton, Alberta, Canada.
Yanlin
Y
Wang
Departments of Neurobiology, Neurology and Pathology, The University of Chicago, Chicago, Illinois, United States of America.
Gopal
G
Thinakaran
Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada; Centre for Prions and Protein Folding Diseases, University of Alberta, Edmonton, Alberta, Canada; Department of Medicine (Neurology), University of Alberta, Edmonton, Alberta, Canada.
Satyabrata
S
Kar
D000544:Alzheimer Disease / Q000235:genetics* / Q000473:pathology; D000818:Animals; D002460:Cell Line; D016000:Cluster Analysis; D005347:Fibroblasts; D005786:Gene Expression Regulation; D051379:Mice; D017527:Receptor, IGF Type 2 / Q000235:genetics*; D015203:Reproducibility of Results; D059467:Transcriptome
D017527:Receptor, IGF Type 2